| Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates. |
Samuele A, Bisi S, Kataropoulou A, La Regina G, Piscitelli F, Gatti V, Silvestri R, Maga G |
2011 |
| Anti-HIV-1 activity in vitro of ceftazidime degradation products. |
Hobi R, Hübscher U, Neftel K, Alteri E, Poncioni B, Walker MR, Woods-Cook K, Schneider P, Lazdins JK |
2001 |
| Nitroimidazoles Part 6. Synthesis, structure and in vitro anti-HIV activity of new 5-substituted piperazinyl-4-nitroimidazole derivatives. |
Al-Masoudi NA, Al-Soud YA, De Clercq E, Pannecouque C |
2007 |
| Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. |
Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF |
2000 |
| HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset). |
Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S |
2003 |
| Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide. |
De Martino G, La Regina G, Ragno R, Coluccia A, Bergamini A, Ciaprini C, Sinistro A, Maga G, Crespan E, Artico M, Silvestri R |
2006 |
| Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents. |
Campiani G, Fabbrini M, Morelli E, Nacci V, Greco G, Novellino E, Maga G, Spadari S, Bergamini A, Faggioli E, Uccella I, Bolacchi F, Marini S, Coletta M, Fracasso C, Caccia S |
2000 |
| Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects. |
Turner D, Roldan A, Brenner BG, Moisi DD, Routy JP, Wainberg MA |
2004 |
| Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. |
Doualla-Bell F, Gaseitsiwe S, Ndungú T, Modukanele M, Peter T, Novitsky V, Ndwapi N, Tendani G, Avalos A, Wester W, Bussmann H, Cardiello P, Marlink RG, Moffat H, Thior I, Wainberg MA, Essex M |
2004 |
| An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase. |
Chamorro C, Camarasa MJ, Pérez-Pérez MJ, De Clercq E, Balzarini J, San Félix A |
1998 |
| Synthesis and antiviral activity of some 5'-N-phthaloyl-3'-azido-2',3'-dideoxythymidine analogues. |
Balzarini J, De Clercq E, Kaminska B, Orzeszko A |
2003 |
| Synthesis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles: non-nucleoside HIV-1 reverse transcriptase inhibitors. |
Chimirri A, Monforte P, Rao A, Zappalà M, Monforte AM, De Sarro G, Pannecouque C, Witvrouw M, Balzarini J, De Clercq E |
2001 |
| Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate. |
Frankel FA, Coutsinos D, Xu H, Wainberg MA |
2007 |
| Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. |
Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA |
2010 |
| Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC. |
Richard N, Salomon H, Oliveira M, Rando R, Mansour T, Gu Z, Wainberg MA |
2000 |
| Anti-HIV-1 activity of benzothiadiazine dioxide. |
Martinez A, Gil C, Castro A, Perez C, Witvrouw M, Pannecouque C, Balzarini J, De Clercq E |
2001 |
| Synthesis and antiviral activity of 1,3-disubstituted uracils against HIV-1 and HCMV. |
Maruyama T, Kozai S, Yamasaki T, Witvrouw M, Pannecouque C, Balzarini J, Snoeck R, Andrei G, De Clercq E |
2003 |
| Structure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors. |
Bonache MC, Chamorro C, Lobatón E, De Clercq E, Balzarini J, Velázquez S, Camarasa MJ, San-Félix A |
2003 |
| Synthesis, solution conformation and anti-HIV activity of novel 3'-substituted-2',3'-dideoxy-5-hydroxymethyluridines and their 4,5-substituted analogues. |
Poznanski J, Bretner M, Kulikowski T, Balzarini J, Van Aerschot A, De Clercq E |
2003 |
| Treatment of visna virus infection in lambs with the acyclic nucleoside phosphonate analogue 9-(2-phosphonylmethoxyethyl)adenine (PMEA). |
Thormar H, Georgsson G, Gunnarsson E, Naesens L, Torsteinsdóttir S, Balzarini J, De Clercq E |
1998 |
| In search of authentic inhibitors of HIV-1 integration. |
Debyser Z, Cherepanov P, Van Maele B, De Clercq E, Witvrouw M |
2002 |
| Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry. |
Witvrouw M, Pannecouque C, Fikkert V, Hantson A, Van Remoortel B, Hezareh M, De Clercq E, Brown SJ |
2003 |
| Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. |
De Clercq E, Schols D |
2001 |
| TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization. |
Camarasa MJ, Velázquez S, San-Félix A, Pérez-Pérez MJ |
2005 |